Viewing data from:

RETIN-A

NDA

TRETINOIN | N017579 | VALEANT INTERNATIONAL BARBADOS SRL

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

94 trials from ClinicalTrials.gov — 1 recruiting, 2 active, 67 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer NCT04241276	Phase 2	Active	Queen Mary University of London	170	2020-04-30 → 2029-02-28
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia NCT02339740	Phase 3	Active	Children's Oncology Group	158	2015-07-21 → 2029-06-30
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia NCT01409161	Phase 2	Recruiting	M.D. Anderson Cancer Center	151	2011-10-05 → 2027-12-18
A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products NCT01313728	Phase 4	Completed	Bausch Health Americas, Inc.	26	2010-12 → 2011-01
Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer NCT00100906	Phase 2	Completed	H. Lee Moffitt Cancer Center and Research Institute	18	2004-08 → 2013-07
Tretinoin With or Without Fenretinide in Treating Patients With Dysplastic Nevus Syndrome NCT00003601	Phase 2	Completed	Eastern Cooperative Oncology Group	38	1999-02-23 → 2004-03-02
Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes NCT00382200	Phase 1/2	Completed	Memorial Sloan Kettering Cancer Center	54	2006-07 → 2023-01-05
Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face NCT00919191	Phase 4	Completed	Bausch Health Americas, Inc.	26	2009-04 → 2009-05
Proof of Concept Study to Investigate the Recurrence of Acne Post Isotretinoin NCT00939133	Phase 4	Completed	Dermatrials Research	20	2009-07 → 2010-12
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia NCT00003934	Phase 3	Completed	National Cancer Institute (NCI)	420	1999-06

Source: ClinicalTrials.gov. Trials matched by ingredient name.

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 2 NDCs

Highest NADAC/Unit

$3.67

per gm

Lowest NADAC/Unit

$2.59

per gm

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00378808615TRETINOIN 0.025% GEL	$3.67	GM	Generic	—	2026-06-17
00378808645TRETINOIN 0.025% GEL	$2.59	GM	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 8 NDCs (4 FSS, 4 Big4)

Lowest Price

$9.61

Highest Price

$127.21

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00378-8086-15TRETINOIN 0.025% GEL,TOP	$35.30	FSS	Mylan Pharmaceuticals, Inc.	12/31/2027
00378-8086-15TRETINOIN 0.025% GEL,TOP	$20.08	Big4	Mylan Pharmaceuticals, Inc.	12/31/2027
00378-8086-45TRETINOIN 0.025% GEL,TOP	$127.21	FSS	Mylan Pharmaceuticals, Inc.	12/31/2027
00378-8086-45TRETINOIN 0.025% GEL,TOP	$45.72	Big4	Mylan Pharmaceuticals, Inc.	12/31/2027
00187-5170-15RETIN-A 0.025% TOP GEL	$10.78	FSS	Bausch Health US, LLC	04/30/2026
00187-5170-15RETIN-A 0.025% TOP GEL	$9.61	Big4	Bausch Health US, LLC	04/30/2026
00187-5170-45RETIN-A 0.025% TOP GEL	$29.40	FSS	Bausch Health US, LLC	04/30/2026
00187-5170-45RETIN-A 0.025% TOP GEL	$29.40	Big4	Bausch Health US, LLC	04/30/2026

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain6 active DMFs4 inactive

5 active API suppliers hold Drug Master Files for this ingredient.

SIEGFRIED PHARMACHEMIKALIEN MINDEN GMBHTRETINOIN

DMF 34561978

OLON SPATRETINOIN

DMF 74741988

AMCOL HEALTH AND BEAUTY SOLUTIONS INCTRETINOIN 4% IN POLY-POREr POLYMER (TRETINOIN IN ALLYL METHACRYLATES CROSSPOLYMER)

DMF 231862009

OLON SPATRETINOIN TYPE 2

DMF 251922011

BIOPHORE INDIA PHARMACEUTICALS PVT LTDTRETINOIN

DMF 269222013

CHONGQING HUAPONT PHARMACEUTICAL CO LTDTRETINOIN

DMF 273982013

DSM NUTRITIONAL PRODUCTS LTDInactiveTRETINOIN (ALL-TRANS-RETINDE, ACID)

DMF 77341988

SHANGHAI NO 6 PHARMACEUTICAL FACTORYInactiveTRETINOIN

DMF 79961989

HOFFMANN LA ROCHE INCInactiveTRETINOIN CAPSULES

DMF 85921990

RANBAXY LABORATORIES LTDInactiveTRETINOIN USP (NON STERILE BULK)

DMF 244202010

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

3 letters from Drugs@FDA

Date	Submission	Document
Jun 10, 2002	SUPPL -18	View Letter (PDF)
Jun 10, 2002	SUPPL -20	View Letter (PDF)
Jun 10, 2002	SUPPL -23	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#002 — 0.025%

RLDAB

0 patents0 exclusivities▴

GEL;TOPICAL | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.